CeGaT Brings New Dimension to Exome Diagnostics
With CeGaT Exome Xtra CeGaT incorporated its long-term expertise and latest scientific knowledge in an innovative diagnostic tool.
CeGaT aims to solve all genetically-caused cases of disease to help physicians state a diagnosis. To pursue this goal, CeGaT incorporated its long-term expertise and latest scientific knowledge in an innovative diagnostic tool: CeGaT Exome Xtra is the most powerful genetic diagnostic option for patients with complex, unspecific, and rare diseases.
CeGaT has been utilizing the power of genetic diagnostics for more than a decade as it introduced gene panels to clinical genetic diagnostics in 2010. Since then, the company has been continuously updating the panels using the newest literature and in close collaboration with clinical experts. Based on all the knowledge gained, CeGaT Exome Xtra is the latest innovation in genetic diagnostics, particularly suitable for solving the most complex patient cases.
With CeGaT Exome Xtra, patients and their treating physicians benefit from a unique approach that combines the advantages of whole-exome sequencing (WES) and whole-genome sequencing (WGS), while avoiding their disadvantages. It outperforms commercially available WES and WGS and increases diagnostic yield.
More information can be found here.
CeGaT GmbH, Tuebingen (Germany), was founded by Saskia Biskup, M.D., PhD, and Dirk Biskup, PhD, in 2009. As a service provider in the field of medicine and biotechnology, CeGaT offers decoding of genetic information and the medical interpretation of the data. CeGaT is the first company in the world to combine human-genetic diagnostics with high-throughput sequencing, a new method for analyzing genetic makeup. In 2010, CeGaT developed so-called “diagnostics panels,” which made it possible to simultaneously decode all of the genes relevant to a disease for the first time.